CERo Therapeutics Statistics
Share Statistics
CERo Therapeutics has 191.55M shares outstanding. The number of shares has increased by 1187.21% in one year.
| Shares Outstanding | 191.55M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 273.65% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 116.22M |
| Failed to Deliver (FTD) Shares | 3.50M |
| FTD / Avg. Volume | 4.65% |
Short Selling Information
The latest short interest is 1.60M, so 0.83% of the outstanding shares have been sold short.
| Short Interest | 1.60M |
| Short % of Shares Out | 0.83% |
| Short % of Float | 1.38% |
| Short Ratio (days to cover) | 0.29 |
Valuation Ratios
The PE ratio is -28312.86 and the forward PE ratio is null.
| PE Ratio | -28312.86 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -5.06 |
| P/FCF Ratio | -47254.42 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for CERo Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.65, with a Debt / Equity ratio of -0.11.
| Current Ratio | 1.65 |
| Quick Ratio | 1.65 |
| Debt / Equity | -0.11 |
| Total Debt / Capitalization | -12.3 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is 24.1%.
| Return on Equity (ROE) | 0% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | 24.1% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -317.03 |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 94.82K |
| Effective Tax Rate | -0.04 |
Stock Price Statistics
The stock price has increased by -99.47% in the last 52 weeks. The beta is -0.46, so CERo Therapeutics 's price volatility has been lower than the market average.
| Beta | -0.46 |
| 52-Week Price Change | -99.47% |
| 50-Day Moving Average | 0.12 |
| 200-Day Moving Average | 0.54 |
| Relative Strength Index (RSI) | 39.44 |
| Average Volume (20 Days) | 75.25M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -2.93M |
| Net Income | -2.54K |
| EBITDA | -2.44M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.39 |
Balance Sheet
The company has 96.87K in cash and 1.55M in debt, giving a net cash position of -1.46M.
| Cash & Cash Equivalents | 96.87K |
| Total Debt | 1.55M |
| Net Cash | -1.46M |
| Retained Earnings | -14.20M |
| Total Assets | 6.49M |
| Working Capital | -5.71M |
Cash Flow
In the last 12 months, operating cash flow was -1.52K and capital expenditures 4, giving a free cash flow of -1.52K.
| Operating Cash Flow | -1.52K |
| Capital Expenditures | 4 |
| Free Cash Flow | -1.52K |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CERO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -650% |
| FCF Yield | -0.01% |
Analyst Forecast
Currently there are no analyst rating for CERO.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -20.77 |
| Piotroski F-Score | 0 |